Related Experiment Video
Updated: Apr 19, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Association between plasma ceramide levels and endothelial dysfunction in patients with acute coronary syndrome: A
Jie Chen1,2, Yang Cheng2,3, Xingxuan Cai2
1Medical School of Chinese PLA, Beijing, China.
Insights
Elevated plasma levels of ceramide (d18:1/24:0) are linked to endothelial dysfunction in acute coronary syndrome patients, suggesting its potential as a biomarker for vascular risk stratification.
Area of Science:
- Cardiovascular Research
- Lipid Metabolism
- Endothelial Biology
Background:
- Endothelial dysfunction (ED) is a key factor in acute coronary syndrome (ACS), often driven by inflammation and oxidative stress.
- Ceramides, bioactive lipids, are implicated in ED, but their specific role in microvascular function in ACS patients remains unclear.
Purpose of the Study:
- To investigate the association between plasma ceramide species and peripheral microvascular endothelial function in patients with ACS.
- To identify specific ceramide species that may serve as biomarkers for ED in this patient population.
Main Methods:
- Prospective observational study of 80 ACS patients undergoing percutaneous coronary intervention.
- Peripheral endothelial function assessed using the EndoPAT2000® system; ED defined as a reactive hyperemia index <1.67.
- Plasma ceramide species quantified via high-performance liquid chromatography-tandem mass spectrometry; statistical analysis using multivariate logistic regression.
Main Results:
- 57.5% of ACS patients exhibited endothelial dysfunction.
- Plasma ceramide species cer (d18:1/24:0) was significantly elevated in patients with ED (P=.045).
- Cer (d18:1/24:0) was independently associated with ED (OR=2.83, P=.034) and showed a trend of declining endothelial function with increasing tertiles (P for trend=.03).
Conclusions:
- Plasma cer (d18:1/24:0) is independently associated with impaired endothelial function in ACS patients.
- Elevated cer (d18:1/24:0) in ED patients, even on standard therapies, suggests a role in residual ED.
- Cer (d18:1/24:0) may be a valuable candidate biomarker for vascular risk stratification in ACS.
Abstract:
Ceramides are bioactive lipids that contribute to endothelial dysfunction (ED) by promoting inflammation and oxidative stress. However, whether ceramide levels are linked to peripheral microvascular endothelial function in patients with acute coronary syndrome (ACS) is not well understood. We conducted a prospective observational study of 80 ACS patients undergoing percutaneous coronary intervention at a single center. Peripheral endothelial function was assessed using the EndoPAT2000® system. ED was defined as a reactive hyperemia index <1.67. Plasma ceramide species were quantified using high-performance liquid chromatography coupled with tandem mass spectrometry. The patients were stratified by ED status, ceramide level tertiles, and subgroup clinical characteristics. Multivariate logistic regression was used to determine the odds ratios and 95% confidence intervals for ED. ED was present in 57.5% of the patients. No significant differences were observed in age, gender, traditional cardiovascular risk factors, or lipid parameters between ED and non-ED groups. Among the 7 ceramide species analyzed, cer (d18:1/24:0) was significantly elevated in the ED group (P = .045). Cer (d18:1/24:0) was independently associated with ED (odds ratios = 2.83; 95% confidence intervals: 1.08-7.44; P = .034). Reactive hyperemia index values declined across tertiles of cer (d18:1/24:0) (P for trend = .03). Among patients on standard medications such as statins, β-blockers, or angiotensin-converting enzyme inhibitors (ACEI)/ARB) therapy, cer (d18:1/24:0) levels were still markedly higher in those with ED than in those without (all P < .05). Plasma cer (d18:1/24:0) is independently associated with impaired endothelial function in ACS patients. Its elevated levels in patients with ED despite receiving standard cardiovascular therapies suggest its potential role in residual ED and indicate its value as a candidate biomarker for vascular risk stratification.
More Related Videos
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
08:51Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome I: Introduction
Coronary Artery Disease II: Pathophysiology
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease I: Introduction